Glucose AUC0-2h

1. HDM1005 decreases glucose AUC0-2h in humans.

   “After single and multiple doses, we observed significant and dose-dependent mean reduction in 0 to 2 h glucose AUC relative to placebo.”

   Human trialSAD and MAD cohorts

   Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HDM1005)—A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on HDM1005